Avecho Biotechnology Limited · ASX:AVE
Avecho Biotechnology — Shareholder Meeting (July 2020)
16 slides from Avecho Biotechnology's shareholder meeting presentation, Jul 13, 2020
Slide 1: CEO Presentation
For personal use only July 2020 CEO Presentation www.avecho.com.au | ASX:AVE
Slide 2: Safe Harbour Statement
Safe Harbour Statement For personal use only This presentation, and any representations made before, during or after the presentation, may include forward- looking statements that are inherently subject to risks and uncertainties. These statements relate to, but are not limited to: (1) the safety or
Slide 3: Company Snapshot
Company Snapshot For personal use only Shares 1,577M Avecho – 6mth price and volume Market cap $14M 0.009 Options 3.8M 0.008 0.007 Cash 1 $3.1M 0.006 Last qtr gross burn 1 ($0.5M) 0.005 0.004 0.003 Headquarters Melbourne 0.002 Board Greg Collier (Chair) 0.001 Ross Murdoch (NED) David Segal (NED) Mat
Slide 4: Overview of Avecho's TPM technology
Overview of Avecho’s TPM® technology For personal use only TPM® is a proprietary combination of two forms of phosphorylated vitamin E Propofol TPM® TPM® is a unique excipient that encapsulates drug molecules TPM® has been used to formulate drugs to improve their: - solubility - stability - oral bioa
Slide 5: Strategic Focus
Strategic Focus For personal use only Avecho has a clear, strategic focus to deliver on two fronts: Realise value from its portfolio of existing human Leverage its proprietary TPM® platform to develop and animal health assets new cannabinoid-based pharmaceuticals • Minimal investment going forward •
Slide 6: International advisory firm engaged to broaden outreach
International advisory firm engaged to broaden outreach For personal use only Priority Prospective Priority products for licensing with the aim to Assets ready for ongoing business development secure a commercial deal for 1 or more of these effort and presentation to potential partners over products
Slide 7: Cannabinoid Pharmaceuticals
For personal use only Cannabinoid Pharmaceuticals
Slide 8: Cannabinoid-based Pharmaceuticals
Cannabinoid-based Pharmaceuticals For personal use only In the past decade, there has been a transformational shift resulting from a recognition of the therapeutic potential of cannabis and cannabis extracts The majority of countries around the world have recently enacted legalisation permitting the
Slide 9: Growing market for therapeutic uses of cannabis
Growing market for therapeutic uses of cannabis For personal use only • In more mature markets (Canada, Colorado Australian approvals for medicinal cannabis prescriptions2 and California), around 1-2% of the population 10,000 45,000 use cannabis products for therapeutic purposes 9,000 40,000 • In Au
Slide 10: Medical market likely to focus on pharmaceutical products
Medical market likely to focus on pharmaceutical products Pharmaceutically developed products are expected to dominate the medical For personal use only cannabis market in the long term: - standardised pharmaceutical delivery formats - clinical safety and efficacy data - registered products are phys
Slide 11: TPM is ideal for pharmaceutical formulation of cannabinoids
TPM® is ideal for pharmaceutical formulation of cannabinoids For personal use only Cannabinoids (the key active compounds in cannabis) are oil soluble molecules with low solubility in water Oil soluble molecules have poor oral bioavailability, which is also true for cannabinoids (3-8% absorbed) This
Slide 12: Focus is on developing pharmaceutical cannabinoid products
Focus is on developing pharmaceutical cannabinoid products For personal use only Avecho intends to use TPM® to develop cannabinoid-based pharmaceuticals: - with known and consistent dosing - delivered in a familiar, pharmaceutical format - backed by robust clinical evidence - able to be manufactured
Slide 13: Plan for developing TPM formulation of cannabinoids
Plan for developing TPM® formulation of cannabinoids For personal use only PROOF OF FORMULATION PRECLINICAL CLINICAL CONCEPT DEVELOPMENT STUDIES STUDIES COMPLETED IN PROGRESS LATE 2020 2021 Demonstrated that TPM® Initial formulation tests Animal studies Human safety, can improve the solubility under
Slide 14: Anticipated news over next months
Anticipated news over next 12 months For personal use only Initial cannabinoid formulation development with TPM® Preclinical studies evaluating TPM® cannabinoids First-in-man studies using TPM®-formulated cannabinoids Disease-specific clinical trials using TPM®-cannabinoids Commercial licence or sal
Slide 15: Questions
For personal use only July 2020 Questions
Slide 16: Contact Dr Paul Gavin
For personal use only Contact Dr Paul Gavin Chief Executive Officer +61 3 9002 5000 pgavin@avecho.com.au Melbourne Office Unit A8, 2A Westall Road Hallmarc Business Park Clayton VIC 3168 Australia Tel: +61 3 9002 5000 Email: info@avecho.com.au July 2020 16
Avecho Biotechnology — Shareholder Meeting (July 2020) on 6ix